The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts.
about
Inhibition of TRIP1/S8/hSug1, a component of the human 19S proteasome, enhances mitotic apoptosis induced by spindle poisonsPreclinical evaluation of the proteasome inhibitor bortezomib in cancer therapyRandomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.Proteasome inhibitors in glioblastomaPlatinum-containing compound platinum pyrithione suppresses ovarian tumor proliferation through proteasome inhibitionEnhancement of docetaxel anticancer activity by a novel diindolylmethane compound in human non-small cell lung cancerTargeted therapies for pancreatic cancer.Biological approaches to therapy of pancreatic cancer.The treatment of traumatic brain injury with velcade.Penetration of anticancer drugs through tumour tissue as a function of cellular packing density and interstitial fluid pressure and its modification by bortezomib.Inhalation delivery of a novel diindolylmethane derivative for the treatment of lung cancerA novel proteasome inhibitor acting in mitochondrial dysfunction, ER stress and ROS production.IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosisFlavopiridol downregulates hypoxia-mediated hypoxia-inducible factor-1alpha expression in human glioma cells by a proteasome-independent pathway: implications for in vivo therapyBortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation studyAmblyomin-X induces ER stress, mitochondrial dysfunction, and caspase activation in human melanoma and pancreatic tumor cell.Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trialsProteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.Proteasome inhibition enhances antitumour effects of gemcitabine in experimental pancreatic cancer.A versatile nanoplatform for synergistic combination therapy to treat human esophageal cancer.Efficacy of aerosolized celecoxib encapsulated nanostructured lipid carrier in non-small cell lung cancer in combination with docetaxel.The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomibTargeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL.Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
P2860
Q24301844-CDE3BF9F-8CB7-4563-8798-14DFE462FB79Q24814325-3F381485-EAB9-4615-AFD0-9F38A01336FCQ33159653-C679518B-4728-4357-A507-1DADEB2D0C84Q33598931-4894DA4F-70A3-438B-BDE8-647E3331F01AQ33801982-2B28C647-8EDC-4D72-B5C7-AA2CF68DB035Q33837550-14EF4155-1A84-476B-9B0D-F8FED2EA69C8Q33899923-31145D1C-FCCA-498A-825A-54ADF63F172CQ33899938-73FC33D4-25B2-4C7C-A62C-FD50D746C77EQ34254813-58B7297D-9FB8-4C37-ABB3-EF1F60481E4DQ34294361-32863100-67E6-4033-A870-F4A4FD70782FQ34300257-1ED94D00-0144-4B4D-B792-FCA85AB5C4E3Q34414191-AE0A3096-241A-466B-A992-DB43849919F8Q34598755-CD0952E5-54C3-43F5-B24B-61C672C111A8Q35800503-71BA5DB6-535D-4147-A1C6-2D3E1088E8B3Q36667443-904FC890-8254-405C-A798-18D6834FEA66Q36762799-4683555B-1F69-4521-A71C-C87B30680A93Q37017342-26005C1C-BAFE-449C-99DD-45BB8AFDAFD2Q37414098-BC83F09E-3B85-4A36-BB08-D6F3719F94E3Q37449396-EEBACBF0-BB47-4E33-AB01-711CC8B6C7A8Q38701979-7AF23475-D261-4C7D-87E9-0CFFDD15ACDBQ39202347-C6C6810B-4B23-4CFB-8101-D477294F37A2Q42037254-D022D2F6-B4A6-485C-8937-6CB972851009Q42115123-9276CB5C-BA3E-4BB8-A9B3-BCB0CEE2952FQ42176458-6DCAE2D4-47BF-49DA-A4B8-B31DCA8D2639
P2860
The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
The proteasome inhibitor borte ...... n pancreatic tumor xenografts.
@ast
The proteasome inhibitor borte ...... n pancreatic tumor xenografts.
@en
The proteasome inhibitor borte ...... n pancreatic tumor xenografts.
@nl
type
label
The proteasome inhibitor borte ...... n pancreatic tumor xenografts.
@ast
The proteasome inhibitor borte ...... n pancreatic tumor xenografts.
@en
The proteasome inhibitor borte ...... n pancreatic tumor xenografts.
@nl
prefLabel
The proteasome inhibitor borte ...... n pancreatic tumor xenografts.
@ast
The proteasome inhibitor borte ...... n pancreatic tumor xenografts.
@en
The proteasome inhibitor borte ...... n pancreatic tumor xenografts.
@nl
P2093
P1476
The proteasome inhibitor borte ...... an pancreatic tumor xenografts
@en
P2093
Bridget Sweeney-Gotsch
David J McConkey
Ryan Takamori
Steffan T Nawrocki
P577
2004-01-01T00:00:00Z